The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment

Biochemical and Biophysical Research Communications

Volumn 410, Issue 3, 2011, Pages 494-500

  Davis, Benjamin B ^a   Liu, Jun Yan ^a   Tancredi, Daniel J ^b   Wang, Lei ^a   Simon, Scott I ^c   Hammock, Bruce D ^a   Pinkerton, Kent E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California Davis   (United States)

Author keywords

Adhesion molecule; Chronic obstructive pulmonary disease; Epoxyeicosatrienoic acids; Inflammation; Leukocyte recruitment; Lipids; Lung; Soluble epoxide hydrolase

Indexed keywords

12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID BUTYL ESTER; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; [1 (1 METHANESULFONYLPIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXYPHENYL)UREA]; ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; TOBACCO SMOKE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LEUKOCYTE RECRUITMENT; LUNG BLOOD VESSEL; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHI; CELL ADHESION MOLECULES; CELL MOVEMENT; ENZYME INHIBITORS; EPOXIDE HYDROLASES; LEUKOCYTES; LUNG; MALE; PNEUMONIA; RATS; RATS, INBRED SHR; SMOKING; TOBACCO;

NICOTIANA TABACUM; RATTUS;

EID: 79960050762     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.008     Document Type: Article

References (39)

1. Papoff P. Infection, neutrophils, and hematopoietic growth factors in the pathogenesis of neonatal chronic lung disease. Clin. Perinatol. 2000, 27(viii):717-731.
2. Moraes T.J., Zurawska J.H., Downey G.P. Neutrophil granule contents in the pathogenesis of lung injury. Curr. Opin. Hematol. 2006, 13:21-27.
3. Barbosa-Sicard E., Fromel T., Keseru B., Brandes R.P., Morisseau C., Hammock B.D., Braun T., Kruger M., Fleming I. Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J. Biol. Chem. 2009, 284:28156-28163. pii:M109.054759, doi:10.1074/jbc.M109.054759.
4. Inceoglu B., Jinks S.L., Schmelzer K.R., Waite T., Kim I.H., Hammock B.D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006, 79:2311-2319. pii:S0024-3205(06)00597-2, doi:10.1016/j.lfs.2006.07.031.
5. Inceoglu B., Jinks S.L., Ulu A., Hegedus C.M., Georgi K., Schmelzer K.R., Wagner K., Jones P.D., Morisseau C., Hammock B.D. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc. Natl. Acad. Sci. USA 2008, 105:18901-18906. pii:0809765105, doi:10.1073/pnas.0809765105.
6. Liu Y., Yang J., Inceoglu B., Qiu H., Ulu A., Hwang S.H., Chiamvimonvat N., Hammock B.D. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem. Pharmacol. 2010, 79:880-887. pii:S0006-2952(09)00940-X, doi:10.1016/j.bcp.2009.10.025.
7. Liu J.Y., Tsai H.J., Hwang S.H., Jones P.D., Morisseau C., Hammock B.D. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br. J. Pharmacol. 2009, 156:284-296. pii: BPH009, doi:10.1111/j.1476-5381.2008.00009.x.
8. Liu J.Y., Park S.H., Morisseau C., Hwang S.H., Hammock B.D., Weiss R.H. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol. Cancer Ther. 2009, 8:2193-2203. pii:1535-7163.MCT-09-0119, doi:10.1158/1535-7163.MCT-09-0119.
9. Liu Y., Zhang Y., Schmelzer K., Lee T.S., Fang X., Zhu Y., Spector A.A., Gill S., Morisseau C., Hammock B.D., Shyy J.Y. The antiinflammatory effect of laminar flow: the role of PPARgamma epoxyeicosatrienoic acids and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA 2005, 102:16747-16752. pii:0508081102, doi:10.1073/pnas.0508081102.
10. Schmelzer K., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., Hammock B. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA 2005.
11. Schmelzer K.R., Inceoglu B., Kubala L., Kim I.H., Jinks S.L., Eiserich J.P., Hammock B.D. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA 2006, 103:13646-13651. pii:0605908103, doi:10.1073/pnas.0605908103.
12. Harder D.R., Campbell W.B., Roman R.J. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J. Vasc. Res. 1995, 32:79-92.
13. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
14. Fitzpatrick F.A., Ennis M.D., Baze M.E., Wynalda M.A., McGee J.E., Liggett W.F. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J. Biol. Chem. 1986, 261:15334-15338.
15. Zeldin D.C., Kobayashi J., Falck J.R., Winder B.S., Hammock B.D., Snapper J.R., Capdevila J.H. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem. 1993, 268:6402-6407.
16. Fang X., Moore S.A., Stoll L.L., Rich G., Kaduce T.L., Weintraub N.L., Spector A.A. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am. J. Physiol. 1998, 275:H2113-H2121.
17. Smith K.R., Uyeminami D.L., Kodavanti U.P., Crapo J.D., Chang L.Y., Pinkerton K.E. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic. Biol. Med. 2002, 33:1106-1114. pii:S0891584902010031.
18. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. USA 2005, 102:2186-2191.
19. Zhong C.Y., Zhou Y.M., Douglas G.C., Witschi H., Pinkerton K.E. MAPK/AP-1 signal pathway in tobacco smoke-induced cell proliferation and squamous metaplasia in the lungs of rats. Carcinogenesis 2005, 26:2187-2195. pii:bgi189, doi:10.1093/carcin/bgi189.
20. Yu B., Kodavanti U.P., Takeuchi M., Witschi H., Pinkerton K.E. Acute tobacco smoke-induced airways inflammation in spontaneously hypertensive rats. Inhal. Toxicol. 2008, 20:623-633. pii:792913012, doi:10.1080/08958370701861538.
21. Bolton S.J., Pinnion K., Oreffo V., Foster M., Pinkerton K.E. Characterisation of the proximal airway squamous metaplasia induced by chronic tobacco smoke exposure in spontaneously hypertensive rats. Respir. Res. 2009, 10:118. pii:1465-9921-10-118, doi:10.1186/1465-9921-10-118.
22. Teague S.V., Pinkerton K.E., Goldsmith M., Gebremichael A., Chang S., Jenkins R.A., Moneyhun J.H. Sidestream cigarette-smoke generation and exposure system for environmental tobacco-smoke studies. Inhal. Toxicol. 1994, 6:79-93.
23. Christensen P.J., Kim S., Simon R.H., Toews G.B., Paine R. Differentiation-related expression of ICAM-1 by rat alveolar epithelial cells. Am. J. Respir. Cell. Mol. 1993, 8:9-15.
24. Paine R., Morris S.B., Jin H., Baleeiro C.E., Wilcoxen S.E. ICAM-1 facilitates alveolar macrophage phagocytic activity through effects on migration over the AEC surface. Am. J. Physiol.-Lung C 2002, 283:L180-L187. 10.1152/ajplung.00430.2001.
25. Moran J.H., Weise R., Schnellmann R.G., Freeman J.P., Grant D.F. Cytotoxicity of linoleic acid diols to renal proximal tubular cells. Toxicol. Appl. Pharmacol. 1997, 146:53-59.
26. Moran J.H., Mitchell L.A., Bradbury J.A., Qu W., Zeldin D.C., Schnellmann R.G., Grant D.F. Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol. Appl. Pharmacol. 2000, 168:268-279.
27. Moran J.H., Mon T., Hendrickson T.L., Mitchell L.A., Grant D.F. Defining mechanisms of toxicity for linoleic acid monoepoxides and diols in Sf-21 cells. Chem. Res. Toxicol. 2001, 14:431-437.
28. Moran J.H., Nowak G., Grant D.F. Analysis of the toxic effects of linoleic acid, 12,13-cis-epoxyoctadecenoic acid, and 12,13-dihydroxyoctadecenoic acid in rabbit renal cortical mitochondria. Toxicol. Appl. Pharmacol. 2001, 172:150-161.
29. Mitchell L.A., Moran J.H., Grant D.F. Linoleic acid cis-epoxyoctadecenoic acids and dihydroxyoctadecadienoic acids are toxic to Sf-21 cells in the absence of albumin. Toxicol. Lett. 2002, 126:187-196.
30. Nowak G., Grant D.F., Moran J.H. Linoleic acid epoxide promotes the maintenance of mitochondrial function and active Na+ transport following hypoxia. Toxicol. Lett. 2004, 147:161-175.
31. Honetschlagerova Z., Huskova Z., Vanourkova Z., Sporkova A., Kramer H.J., Hwang S.H., Tsai H.J., Hammock B.D., Imig J.D., Cervenka L., Kopkan L. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J. Physiol. 2011, 589:207-219. pii:jphysiol.2010.199505, doi:10.1113/jphysiol.2010.199505.
32. Olearczyk J.J., Quigley J.E., Mitchell B.C., Yamamoto T., Kim I.H., Newman J.W., Luria A., Hammock B.D., Imig J.D. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. (Lond) 2009, 116:61-70. pii:CS20080039, doi:10.1042/CS20080039.
33. Huang H., Morisseau C., Wang J., Yang T., Falck J.R., Hammock B.D., Wang M.H. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. Renal. Physiol. 2007, 293:F342-F349. pii:00004.2007, doi:10.1152/ajprenal.00004.2007.
34. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim I.H., Watanabe T., Hammock B.D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005, 46:975-981. pii:01.HYP.0000176237.74820.75, doi:10.1161/01.HYP.0000176237.74820.75.
35. Aboutabl M.E., Zordoky B.N., Hammock B.D., El-Kadi A.O. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J. Cardiovasc. Pharmacol. 2011, 57:273-281. pii:00005344-201103000-00001, doi:10.1097/FJC.0b013e3182055baf.
36. Zhang L.N., Vincelette J., Cheng Y., Mehra U., Chen D., Anandan S.K., Gless R., Webb H.K., Wang Y.X., atherosclerosis Inhibition of soluble epoxide hydrolase attenuated, formation abdominal aortic aneurysm and dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1265-1270. pii:ATVBAHA.109.186064, doi:10.1161/ATVBAHA.109.186064.
37. Ulu A., Davis B.B., Tsai H.J., Kim I.H., Morisseau C., Inceoglu B., Fiehn O., Hammock B.D., Weiss R.H. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J. Cardiovasc. Pharmacol. 2008, 52:314-323. 10.1097/FJC.0b013e318185fa3c.
38. Ai D., Pang W., Li N., Xu M., Jones P.D., Yang J., Zhang Y., Chiamvimonvat N., Shyy J.Y., Hammock B.D., Zhu Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2009, 106:564-569. pii:0811022106. 10.1073/pnas.0811022106.
39. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., Davis B.B., Low R., Hammock B.D., Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA 2006, 103:18733-18738.